Intensity Therapeutics Inc. (INTS) – What Are Brokerages Thinking About This Stock?

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.00.

INTS has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Monday, October 19th. HC Wainwright increased their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th.

Intensity Therapeutics Stock Down 0.3%

Intensity Therapeutics stock opened at $3.18 on Friday. Intensity Therapeutics has a fifty-two week low of $3.09 and a fifty-two week high of $43.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The firm has a 50 day moving average price of $3.87 and a 200 day moving average price of $4.32. The company has a market capitalization of $10.38 million, a PE ratio of -0.89 and a beta of 2.81.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). Research analysts expect that Intensity Therapeutics will post -2.64 earnings per share for the current year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors. The company’s approach is based on its proprietary INTASYL technology, which is intended to enable therapeutic compounds to enter tumor cells directly, promote cancer-cell death and stimulate an immune response against tumor tissue.

Intensity Therapeutics’ lead investigational product, INT230-6, is an intratumoral therapy formulated to deliver anticancer agents directly into tumors.